Should a 66-year-old patient who began low‑dose aspirin (81 mg) at age 50 and has tolerated it well continue the medication indefinitely?

Should This Patient Continue Aspirin?

This 66-year-old patient who began aspirin at age 50 for primary prevention should discontinue aspirin, as current evidence shows no net benefit and increased bleeding risk in adults ≥60 years without established cardiovascular disease.

Key Decision Framework

The critical distinction here is primary versus secondary prevention:

If Started for Primary Prevention (No Prior MI, Stroke, or Coronary Disease)

Stop the aspirin. The 2022 USPSTF guidelines explicitly recommend against aspirin initiation in adults ≥60 years for primary prevention (Grade D recommendation) 1. This represents a major shift from older guidance, driven by recent trials showing:

• No mortality benefit in older adults 1, 2
• Increased bleeding risk that outweighs cardiovascular benefits, particularly in those >70 years 3
• The ASPREE trial specifically demonstrated aspirin cessation in healthy older adults (≥70 years) was safe, with reduced bleeding risk and no increase in cardiovascular events 4

The 2019 ACC/AHA Primary Prevention Guidelines downgraded aspirin to Class IIb (may be considered) only for adults 40-59 years with ≥10% 10-year ASCVD risk, and explicitly state it is "potentially harmful" in those >70 years 5.

If Started for Secondary Prevention (History of MI, Stroke, Stent, or Known CAD)

Continue aspirin indefinitely at 81 mg daily. This is a Class I recommendation across all major cardiology guidelines 6, 7, 6, 8, 9, 7. The evidence for secondary prevention remains robust regardless of age:

• Aspirin reduces recurrent cardiovascular events by approximately 25% in patients with established disease 10
• The 81 mg dose is preferred over higher doses (reduces bleeding without compromising efficacy) 6, 9
• Duration: indefinite continuation unless contraindicated 6, 7, 6, 8

Critical Information Needed

To make the definitive recommendation, determine:

1. Was there a prior cardiovascular event? (MI, stroke, TIA, coronary revascularization, peripheral arterial disease)
2. Current bleeding risk factors:
   • History of GI bleeding or peptic ulcer disease
   • Concurrent anticoagulation
   • Uncontrolled hypertension
   • Recent falls or bleeding events

Bleeding Risk Considerations

At age 66, bleeding risk is substantially elevated 3, 11:

• GI bleeding risk increases significantly after age 60, with even greater risk after 70 3
• Major bleeding events increased by 42-59% in primary prevention trials 3, 2
• One study found 1.27% annual GI bleeding rate in older adults on aspirin, with age ≥75 being a significant risk factor 12

If Continuing Aspirin (Secondary Prevention Only)

Consider adding a proton pump inhibitor (PPI) if:

• History of GI bleeding (Class I recommendation) 6
• Age >60 with additional risk factors (Class IIa recommendation) 6
• Concurrent anticoagulation or dual antiplatelet therapy 6

Common Pitfalls to Avoid

1. Don't continue aspirin based solely on "tolerating it well" - bleeding risk increases with age independent of prior tolerance 3, 1
2. Don't confuse colorectal cancer prevention with cardiovascular prevention - while aspirin may reduce CRC risk, this benefit only applies to those <70 years and doesn't justify continuation at age 66 for primary prevention 3
3. Don't assume all patients on aspirin have a secondary prevention indication - many older adults were started on aspirin under outdated primary prevention guidelines 12

Bottom Line Algorithm

Patient on aspirin at age 66 →
├─ History of MI/stroke/stent/CAD? 
│  ├─ YES → Continue 81 mg daily indefinitely
│  │         Consider adding PPI if GI risk factors
│  └─ NO → STOP aspirin
│            (Primary prevention: no net benefit, increased bleeding risk)